65.30SEK-0.61%Mkt Cap: 84.14M $P/E: —Today
Infant Bacterial Therapeutics AB (publ) operates as a clinical stage pharmaceutical company develops and markets drugs to prevent serious neonatal diseases affecting premature infants in Sweden. The company's lead drug c…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap84.14M $
Enterprise Value72.04M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-6.23M $
Revenue/Share—
Last Price65.30 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees6
CountrySE
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B10.62
EPS (TTM)-5.30
EPS (Forward)—
52W Range
43.2554% of range84.30
52W High84.30 SEK
52W Low43.25 SEK
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-61.87%
ROA-40.29%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.92M $
CapEx (TTM)—
FCF Margin—
FCF Yield-4.02%
Net Debt-12.62M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio2.23
Quick Ratio2.21
Book Value/Sh6.130 SEK
Cash/Share9.793 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.13.02M
Float11.23M
Insiders14.52%
Institutions36.74%
Technical
SMA 5065.57 (-0.4%)
SMA 20054.83 (+19.1%)
Beta0.36
S&P 52W Chg18.16%
Avg Vol (30d)4.31K
Avg Vol (10d)5.49K
Technical Indicators
RSI (14)51.3
MACD0.1325
MACD Signal0.3226
MACD Hist.-0.1901
BB Upper67.39 SEK
BB Middle65.75 SEK
BB Lower64.12 SEK
BB Width4.98%
ATR (14)2.515 SEK
Vol Ratio (20d)0.59x